Pharmaceutical Third-Party Logistics Market Size, Share & Trends Analysis Report By Product (Branded, Generic, Biosimilar), By Temperature (Ambient, Refrigerated), By Therapeutic Area, By Manufacturer Size, By Service, By Region,- Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2025-2034

Pharmaceutical Third-Party Logistics Market Size and Growth

The pharmaceutical third-party logistics market size was exhibited at USD 137.5 billion in 2024 and is projected to hit around USD 324.32 billion by 2034, growing at a CAGR of 8.96% during the forecast period 2025 to 2034.

Pharmaceutical Third-Party Logistics Market Size 2024 To 2034

Pharmaceutical Third-Party Logistics Market Key Takeaways:

  • The branded drugs segment captured the highest market share of 39.06% in the pharmaceutical third-party logistics industry in 2024.
  • Cell therapy segment is projected to experience the highest CAGR of 9.86%.
  • The ambient segment dominated the pharmaceutical third-party logistics industry with 48% share in 2024
  • The refrigerated segment is expected to experience the highest growth rate during the forecast period.
  • The oncology segment dominated the pharmaceutical third-party logistics industry with 23.02% share in 2024.
  • The storage and shipping segment held the largest share of 43.0% in 2024
  • DSCSA and serialization services are projected to grow at the highest CAGR from 2025 to 2034.
  • The large manufacturer size segment dominated the pharmaceutical third-party logistics industry in 2024.
  • The medium-sized manufacturing segment is expected to experience the fastest growth rate during the forecast period.
  • North America accounted for the largest market share of 39.0% in 2024

U.S. Pharmaceutical Third-Party Logistics Market Size and Growth 2025 to 2034

The U.S. pharmaceutical third-party logistics market size is evaluated at USD 40.2 billion in 2024 and is projected to be worth around USD 95.5 billion by 2034, growing at a CAGR of 8.18% from 2025 to 2034.

U.S. Pharmaceutical Third-Party Logistics Market Size 2024 To 2034

North America accounted for the largest market share of 39.0% in 2024 owing to the region's well-established healthcare infrastructure, advanced logistics networks, and the high demand for pharmaceutical products. The U.S., in particular, is home to a vast number of pharmaceutical manufacturers, distributors, and biotech companies, which heavily rely on 3PL providers for efficient storage, transportation, and compliance with regulatory standards.

Stacked Graph 0

U.S. Pharmaceutical Third-party Logistics Market Trends

The pharmaceutical third-party logistics market in the U.S. is fueled increasing complexity of pharmaceutical supply chains and the demand for efficient distribution of a wide range of drugs, including specialty pharmaceuticals and biologics. The country’s market is one of the largest market globally, and as regulatory standards become more stringent, manufacturers are increasingly turning to 3PL providers to ensure compliance with the Drug Supply Chain Security Act (DSCSA) and other regulations.  In addition, the growing trend of outsourcing logistics to reduce costs and improve efficiency, along with the rise of e-commerce for pharmaceutical products, has further accelerated the demand for 3PL services in the U.S.

Europe Pharmaceutical Third-party Logistics Market Trends

The pharmaceutical third-party logistics market in Europe is experiencing growth due the region's expanding pharmaceutical industry, evolving regulatory environment, and increasing demand for efficient, temperature-controlled logistics. Europe is a hub for pharmaceutical manufacturing and research, which is driving the demand for biologics and other temperature-sensitive drugs and the need for specialized logistics solutions.

The pharmaceutical third-party logistics market in the UK held a significant share in 2024 due to the country's established role as a major pharmaceutical hub in Europe and its robust healthcare infrastructure. The UK is home to numerous global pharmaceutical manufacturers and distributors, and the market benefits from a well-developed logistics network, making it an ideal location for pharmaceutical logistics operations. With the growing demand for specialized logistics services, particularly in temperature-sensitive pharmaceuticals, the UK’s reliance on 3PL providers to ensure compliance with regulatory standards such as GDP and to manage the complexity of international trade is projected to contribute to the market growth.

The pharmaceutical third-party logistics market in France is drive due to an increasing demand for innovative therapies, and the country’s strategic position within Europe. The country’s regulatory environment, which includes strict compliance requirements for drug distribution, is also one of the factors contributing to the market growth as most of the companies are turning to third party logistics providers that can ensure timely and secure deliveries while adhering to Good Distribution Practices (GDP).

The pharmaceutical third-party logistics market in Germany is anticipated to grow significantly over the forecast period. The country has a high volume of drug production, which requires efficient supply chain management to ensure timely distribution of products both domestically and internationally. The rise in demand for biologics, vaccines, and other temperature-sensitive products has further fueled the need for cold chain logistics solutions.

Asia Pacific Pharmaceutical Third-party Logistics Market Trends

The Asia Pacific pharmaceutical third-party logistics market is projected to grow at the highest CAGR over the forecast period. The growth of the market is mainly due to the increasing demand for healthcare products, rising investments in the pharmaceutical sector, and the region's expanding manufacturing capabilities. Countries like China, India, and Japan are becoming key players in the global pharmaceutical market, driving the need for efficient logistics solutions to support both local and international distribution. The rapid growth of the healthcare infrastructure, coupled with rising consumer awareness and the demand for innovative drugs and biologics, has created an urgent need for 3PL providers to offer specialized services, including temperature-controlled logistics and regulatory compliance solutions.

The pharmaceutical third-party logistics market in China is expected to grow over the forecast period. The growth is driven due to the country’s rapidly expanding pharmaceutical industry, increased government investments in healthcare, and rising domestic demand for both traditional and biologic drugs. Moreover, growing country’s focus towards improving healthcare infrastructure and expanding access to advanced treatments is driving demand for temperature-sensitive logistics services.

Japan pharmaceutical third-party logistics Market is witnessing significant growth over the forecast period. The growth is due to the country's aging population coupled with growing demand for effective healthcare solutions. Moreover, Japan's advanced healthcare system and large pharmaceutical industry has created a significant demand for specialized logistics solutions, particularly for temperature-sensitive products such as biologics and vaccines.

India pharmaceutical third-party logistics Market is witnessing a considerable growth due to the country's expanding pharmaceutical manufacturing sector, increasing demand for healthcare products, and a rapidly growing healthcare infrastructure. The country is one of the largest producers of generic medicines globally and has witnessed a significant surge in both domestic and international demand for pharmaceutical products. This growth is driving the need for specialized logistics solutions, including temperature-controlled storage and transportation, to ensure the safe distribution of a wide range of drugs, particularly biologics and vaccines.

Latin America Pharmaceutical Third-Party Logistics Market Trends

The Latin America pharmaceutical third-party logistics (3PL) Market is projected to grow over the forecast period. The growth in the region is due to the increasing demand for pharmaceutical products, improvements in healthcare infrastructure, and rising pharmaceutical manufacturing activities in countries such as Brazil, Mexico, and Argentina. The region’s large and growing population, coupled with the need for better access to healthcare, is driving the need for efficient logistics solutions.

The pharmaceutical third-party logistics (3PL) Market in Brazil is expected to grow over the forecast period due to the country’s increasing pharmaceutical production, expanding healthcare sector, and growing demand for innovative treatments. As Brazil is the largest pharmaceutical market in Latin America, the need for reliable logistics services that can ensure the safe, timely, and compliant distribution of pharmaceuticals would further contribute to the market growth.

Report Scope of Pharmaceutical Third-Party Logistics Market

 Report Coverage  Details
Market Size in 2025 USD 149.82 Billion
Market Size by 2034 USD 324.32 Billion
Growth Rate From 2025 to 2034 CAGR of 8.96%
Base Year 2024
Forecast Period 2025-2034
Segments Covered Product, Temperature, Therapeutic Area, Manufacturer Size, Service
Market Analysis (Terms Used) Value (US$ Million/Billion) or (Volume/Units)
Regional scope North America; Europe; Asia Pacific; Latin America; MEA
Key Companies Profiled CEVA Logistics; Cencora Corporation (ICS); DB SCHENKER; Kuehne+Nagel; Kerry Logistics Network Limited; Cardinal Health; McKesson Corporation; EVERSANA, Thermo Fisher Scientific, Knipper Health

Pharmaceutical Third-Party Logistics Market By Product Insights

The branded drugs segment captured the highest market share of 39.06% in the pharmaceutical third-party logistics industry in 2024. The growth is mainly due to their high market value and established demand. Pharmaceutical companies producing branded drugs often rely on third-party logistics providers to manage the complex and global supply chains necessary for distributing these products. These drugs, often protected by patents, are typically high-margin products that require stringent storage and transportation conditions, especially for temperature-sensitive medications.

Cell therapy segment is projected to experience the highest CAGR of 9.86% due to its potential to treat a wide range of diseases, including cancer, autoimmune disorders, and genetic conditions. Increasing demand for cell-based therapies would subsequently lead to the growing demand for specialized logistics services, particularly in handling and transporting these delicate and time-sensitive products. These therapies often require precise temperature control, unique storage solutions, and real-time monitoring to maintain their viability.

Pharmaceutical Third-Party Logistics Market By Temperature Insights

The ambient segment dominated the pharmaceutical third-party logistics industry with 48% share in 2024 owing to the large volume of pharmaceutical products that do not require temperature-controlled environments. Many over the counter (OTC) drugs, generics, and other non-temperature-sensitive medications are typically stored and transported at room temperature, making ambient logistics the most cost-effective and widely used solution.The ease of managing ambient shipments, combined with the widespread use of these medications globally, are some of the factors contributing to the segment’s growth.

The refrigerated segment is expected to experience the highest growth rate during the forecast period. The growth is driven due to the increasing demand for temperature-sensitive products, such as biologics, vaccines, and cell therapies. These products require precise temperature control throughout their entire supply chain to maintain efficacy and safety. Moreover, with the rapid development of biopharmaceuticals and the growing need for vaccines, the demand for refrigerated logistics services is projected to increase.

Pharmaceutical Third-Party Logistics Market By Therapeutic Area Insights

The oncology segment dominated the pharmaceutical third-party logistics industry with 23.02% share in 2024. The growth is mainly driven due to an increasing incidence of cancer globally coupled with the growing demand for specialized treatments such as chemotherapy, immunotherapy, and targeted therapies. Cancer drugs often require highly regulated and temperature-controlled logistics to ensure their stability and efficacy, leading pharmaceutical companies to rely on third-party logistics providers with advanced cold chain capabilities. Thus, the aforementioned factors are contributing to the segment’s growth.

The neurology segment is expected to experience a lucrative growth rate during the forecast period. The growth is driven due to the growing number of neurology drug pipelines with its subsequent approvals in the coming years. These factors would further boost the demand for specialized pharmaceutical logistics services, including temperature-sensitive and time-critical deliveries.

Pharmaceutical Third-Party Logistics Market By Service Insights

The storage and shipping segment held the largest share of 43.0% in 2024 due to an increasing demand for secure, compliant storage and timely shipping, particularly for temperature-sensitive drugs. Companies rely heavily on securing storage facilities and optimized shipping solutions to maintain the integrity of pharmaceuticals and comply with complex distribution regulations. These factors coupled with increasing global trade and the growing demand for more efficient supply chains is driving the segment’s growth.

Pie Graph 0

DSCSA and serialization services are projected to grow at the highest CAGR from 2025 to 2034. The growth is driven due to the expanding regulatory landscape focused on enhancing drug traceability and combating counterfeit medications. The Drug Supply Chain Security Act requires pharmaceutical companies to serialize their products with unique identifiers, enabling full visibility and traceability from manufacturing to point-of-sale. Moreover, stringent government regulations worldwide to ensure drug safety and integrity, serialization services the demand for efficient logistics services is projected to increase.

Pharmaceutical Third-Party Logistics Market By Manufacturer Size Insights

The large manufacturer size segment dominated the pharmaceutical third-party logistics industry in 2024. The growth is mainly driven due the substantial production volumes and the extensive global distribution networks of major pharmaceutical companies. Large manufacturers typically have a diverse portfolio of products, ranging from generics to branded drugs, which require efficient and reliable logistics solutions to manage the complexities of supply chains across multiple regions. In addition, their ability to invest in advanced technologies, including automated systems and real-time tracking, allows them to optimize logistics operations, reduce costs, and ensure compliance with stringent regulatory standards.

The medium-sized manufacturing segment is expected to experience the fastest growth rate during the forecast period. Medium-sized manufacturers are typically in a phase of growth and innovation, with a focus on developing new products, such as specialized biologics and therapies, that require more tailored logistics services. As these companies grow, they are looking to optimize their supply chains by partnering with third-party logistics providers to ensure reliable and compliant transportation, especially for temperature-sensitive or regulated products. The growing trend of outsourcing logistics functions and the increasing adoption of digital solutions by medium-sized manufacturers is projected to contribute to the pharmaceutical third-party logistics (3PL)industry growth.

Some of the prominent players in the pharmaceutical third-party logistics market include:

  • CEVA Logistics
  • Cencora Corporation (ICS)
  • DB SCHENKER
  • Kuehne+Nagel
  • Kerry Logistics Network Limited
  • Cardinal Health
  • McKesson Corporation
  • EVERSANA
  • Thermo Fisher Scientific
  • Knipper Health

Pharmaceutical Third-Party Logistics Market Recent Developments

  • In September 2024, DSV announced to acquire DB Schenker from Deutsche Bahn for USD 14.74 billion. This acquisition aims to enhance DSV's global network, expertise, and competitiveness, benefiting employees, customers, and investors.

  • In September 2024, CEVA Logistics announced an agreement to take over CMA CGM's freight management responsibilities to enhance CEVA’s business growth while enabling CMA CGM to focus on its core shipping operations. This strategic shift strengthened the company’s partnership and streamlined operations for both companies.

  • In May 2023, Yaral Pharma, the U.S. generics subsidiary of IBSA, has expanded its partnership with EVERSANA to enhance the commercialization of its pain and endocrinology portfolio in the U.S. Through this acquisition, EVERSANA delivered comprehensive support, including third-party logistics (3PL) and operational services, ensuring seamless customer service and market expansion.

Segments Covered in the Report

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the pharmaceutical third-party logistics market

By Product

  • Branded
  • Generic
  • Biosimilar
  • Vaccine
  • Cell Therapy
  • Gene Therapy
  • Others

By Temperature

  • Ambient
  • Refrigerated
  • Frozen
  • Ultra-frozen/Deep-Frozen
  • Cryogenic

By Therapeutic Area

  • Oncology
  • Cardiovascular Diseases
  • Infectious Diseases
  • Neurology
  • Diabetes
  • Nephrology
  • Rheumatology
  • Allergy/Asthma
  • Gastroenterology
  • Ophthalmology
  • Others

By Manufacturer Size

  • Large
  • Medium
  • Small

By Service

  • Storage and Shipping
  • Order-to-cash
  • Title Model
  • DSCSA and Serialization Services
  • Pharmaceutical Sampling
  • Others

By Regional

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa (MEA)

Frequently Asked Questions

The pharmaceutical third-party logistics market size was exhibited at USD 137.5 billion in 2024 and is projected to hit around USD 324.32 billion by 2034, growing at a CAGR of 8.96% during the forecast period 2025 to 2034.

branded drugs segment dominated the (3PL) market with a share of 38.2% in 2024. The growth is mainly due to their high market value and established demand.

North America dominated the pharmaceutical third-party logistics market with a share of 40.0% in 2024. This is attributable to the region\'s well-established healthcare infrastructure, advanced logistics networks, and the high demand for pharmaceutical products.

Some key players operating in the pharmaceutical 3PL market include CEVA Logistics, Cencora Corporation (ICS), DB SCHENKER, Kuehne+Nagel, Kerry Logistics Network Limited, Cardinal Health, McKesson Corporation, EVERSANA, Thermo Fisher Scientific, Knipper Health

Key factors that are driving the market growth include increasing complexity of global supply chains, stringent regulatory compliance, especially for temperature-sensitive products like biologics and vaccines, and globalization of the pharmaceutical industry.

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope

1.2. Market Definitions

1.2.1. Product Segment

1.2.2. Temperature Segment

1.2.3. Therapeutic Area Segment

1.2.4. Manufacturer Size Segment

1.2.5. Service Segment

1.3. Information Analysis

1.3.1. Market Formulation & Data Visualization

1.4. Data Validation & Publishing

1.5. Information Procurement

1.5.1. Primary Research

1.6. Information or Data Analysis

1.7. Market Formulation & Validation

1.8. Market Model

1.9. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook

2.2. Segment Snapshot

2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

3.1. Market Lineage Outlook

3.1.1. Parent Market Outlook

3.1.2. Related/Ancillary Market Outlook

3.2. Market Trends and Outlook

3.3. Market Dynamics

3.3.1. Market Driver Analysis

3.3.1.1. The Rise of E-Commerce

3.3.1.2. Growing Demand for Outsourcing Services

3.3.1.3. Rising Demand for Cold Chain Logistics

3.3.1.4. Growing Applications of Reverse Logistics in Biopharmaceutical Industry

3.3.2. Market Restraint Analysis

3.3.2.1. High Operational Costs

3.3.2.2. Compliance Issues While Outsourcing

3.4. Industry Analysis Tools

3.4.1. Porter’s Five Forces Analysis

3.4.2. PESTEL Analysis

3.4.3. COVID-19 Impact Analysis

Chapter 4. Pharmaceutical Third-Party Logistics (3PL) Services Market: Product Estimates & Trend Analysis

4.1. Segment Dashboard

4.2. Pharmaceutical Third-Party Logistics (3PL) Services Market; Product Movement Analysis

4.3. Pharmaceutical Third-Party Logistics (3PL) Services Size & Trend Analysis, by Product, 2021 to 2034 (USD Million)

4.4. Branded

4.4.1. Branded market estimates and forecasts 2021 to 2034 (USD Million)

4.5. Generic

4.5.1. Generic market estimates and forecasts 2021 to 2034 (USD Million)

4.6. Biosimilar

4.6.1. Biosimilar market estimates and forecasts 2021 to 2034 (USD Million)

4.7. Vaccine

4.7.1. Vaccine market estimates and forecasts 2021 to 2034 (USD Million)

4.8. Cell Therapy

4.8.1. Cell therapy market estimates and forecasts 2021 to 2034 (USD Million)

4.9. Gene Therapy

4.9.1. Gene therapy market estimates and forecasts 2021 to 2034 (USD Million)

4.10. Others

4.10.1. Others market estimates and forecasts 2021 to 2034 (USD Million)

Chapter 5. Pharmaceutical Third-Party Logistics (3PL) Services Market: Temperature Estimates & Trend Analysis

5.1. Segment Dashboard

5.2. Pharmaceutical Third-Party Logistics (3PL) Services Market; Temperature Movement Analysis

5.3. Pharmaceutical Third-Party Logistics (3PL) Services Size & Trend Analysis, by Temperature, 2021 to 2034 (USD Million)

5.4. Ambient

5.4.1. Ambient market estimates and forecasts 2021 to 2034 (USD Million)

5.5. Refrigerated

5.5.1. Refrigerated market estimates and forecasts 2021 to 2034 (USD Million)

5.6. Frozen

5.6.1. Frozen market estimates and forecasts 2021 to 2034 (USD Million)

5.7. Ultra-frozen/Deep-Frozen

5.7.1. Ultra-frozen/Deep-Frozen market estimates and forecasts 2021 to 2034 (USD Million)

5.8. Cryogenic

5.8.1. Cryogenic market estimates and forecasts 2021 to 2034 (USD Million)

Chapter 6. Pharmaceutical Third-Party Logistics (3PL) Services Market: Therapeutic Area Estimates & Trend Analysis

6.1. Segment Dashboard

6.2. Pharmaceutical Third-Party Logistics (3PL) Services Market; Therapeutic Area Movement Analysis

6.3. Pharmaceutical Third-Party Logistics (3PL) Services Size & Trend Analysis, by Therapeutic Area, 2021 to 2034 (USD Million)

6.4. Oncology

6.4.1. Oncology market estimates and forecasts 2021 to 2034 (USD Million)

6.5. Cardiovascular Diseases

6.5.1. Cardiovascular diseases market estimates and forecasts 2021 to 2034 (USD Million)

6.6. Infectious Diseases

6.6.1. Infectious diseases market estimates and forecasts 2021 to 2034 (USD Million)

6.7. Neurology

6.7.1. Neurology market estimates and forecasts 2021 to 2034 (USD Million)

6.8. Diabetes

6.8.1. Diabetes market estimates and forecasts 2021 to 2034 (USD Million)

6.9. Nephrology

6.9.1. Nephrology market estimates and forecasts 2021 to 2034 (USD Million)

6.10. Rheumatology

6.10.1. Rheumatology market estimates and forecasts 2021 to 2034 (USD Million)

6.11. Allergy/Asthma

6.11.1. Allergy/Asthma market estimates and forecasts 2021 to 2034 (USD Million)

6.12. Gastroenterology

6.12.1. Gastroenterology market estimates and forecasts 2021 to 2034 (USD Million)

6.13. Ophthalmology

6.13.1. Ophthalmology market estimates and forecasts 2021 to 2034 (USD Million)

6.14. Others

6.14.1. Others market estimates and forecasts 2021 to 2034 (USD Million)

Chapter 7. Pharmaceutical Third-Party Logistics (3PL) Services Market: Manufacturer Size Estimates & Trend Analysis

7.1. Segment Dashboard

7.2. Pharmaceutical Third-Party Logistics (3PL) Services Market; Manufacturer Size Movement Analysis

7.3. Pharmaceutical Third-Party Logistics (3PL) Services Size & Trend Analysis, by Manufacturer Size, 2021 to 2034 (USD Million)

7.4. Large

7.4.1. Large market estimates and forecasts 2021 to 2034 (USD Million)

7.5. Medium

7.5.1. Medium market estimates and forecasts 2021 to 2034 (USD Million)

7.6. Small

7.6.1. Small market estimates and forecasts 2021 to 2034 (USD Million)

Chapter 8. Pharmaceutical Third-Party Logistics (3PL) Services Market: Service Estimates & Trend Analysis

8.1. Segment Dashboard

8.2. Pharmaceutical Third-Party Logistics (3PL) Services Market; Service Movement Analysis

8.3. Pharmaceutical Third-Party Logistics (3PL) Services Size & Trend Analysis, by Service, 2021 to 2034 (USD Million)

8.4. Storage and Shipping

8.4.1. Storage and Shipping market estimates and forecasts 2021 to 2034 (USD Million)

8.5. Order-to-cash

8.5.1. Order-to-cash market estimates and forecasts 2021 to 2034 (USD Million)

8.6. Title Model

8.6.1. Title Model market estimates and forecasts 2021 to 2034 (USD Million)

8.7. DSCSA and Serialization Services

8.7.1. DSCSA and Serialization Services market estimates and forecasts 2021 to 2034 (USD Million)

8.8. Pharmaceutical Sampling

8.8.1. Pharmaceutical Sampling market estimates and forecasts 2021 to 2034 (USD Million)

8.9. Others

8.9.1. Others market estimates and forecasts 2021 to 2034 (USD Million)

Chapter 9. Regional Business Analysis

9.1. Regional Dashboard

9.2. Market Size & Forecasts and Trend Analysis, 2021 to 2034

9.3. North America

9.3.1. North America Pharmaceutical Third-party Logistics Market, 2021 - 2034 (USD Million)

9.3.2. U.S.

9.3.2.1. Key Country Dynamics

9.3.2.2. Competitive Scenario

9.3.2.3. Regulatory Framework

9.3.2.4. U.S. Pharmaceutical Third-party Logistics Market, 2021 - 2034 (USD Million)

9.3.3. Canada

9.3.3.1. Key Country Dynamics

9.3.3.2. Competitive Scenario

9.3.3.3. Regulatory Framework

9.3.3.4. Canada Pharmaceutical Third-party Logistics Market, 2021 - 2034 (USD Million)

9.3.4. Mexico

9.3.4.1. Key Country Dynamics

9.3.4.2. Competitive Scenario

9.3.4.3. Regulatory Framework

9.3.4.4. Mexico Pharmaceutical Third-party Logistics Market, 2021 - 2034 (USD Million)

9.4. Europe

9.4.1. Europe Pharmaceutical Third-party Logistics Market, 2021 - 2034 (USD Million)

9.4.2. Germany

9.4.2.1. Key Country Dynamics

9.4.2.2. Competitive Scenario

9.4.2.3. Regulatory Framework

9.4.2.4. Germany Pharmaceutical Third-party Logistics Market, 2021 - 2034 (USD Million)

9.4.3. UK

9.4.3.1. Key Country Dynamics

9.4.3.2. Competitive Scenario

9.4.3.3. Regulatory Framework

9.4.3.4. UK Pharmaceutical Third-party Logistics Market, 2021 - 2034 (USD Million)

9.4.4. France

9.4.4.1. Key Country Dynamics

9.4.4.2. Competitive Scenario

9.4.4.3. Regulatory Framework

9.4.4.4. France Pharmaceutical Third-party Logistics Market, 2021 - 2034 (USD Million)

9.4.5. Italy

9.4.5.1. Key Country Dynamics

9.4.5.2. Competitive Scenario

9.4.5.3. Regulatory Framework

9.4.5.4. Italy Pharmaceutical Third-party Logistics Market, 2021 - 2034 (USD Million)

9.4.6. Spain

9.4.6.1. Key Country Dynamics

9.4.6.2. Competitive Scenario

9.4.6.3. Regulatory Framework

9.4.6.4. Spain Pharmaceutical Third-party Logistics Market, 2021 - 2034 (USD Million)

9.4.7. Denmark

9.4.7.1. Key Country Dynamics

9.4.7.2. Competitive Scenario

9.4.7.3. Regulatory Framework

9.4.7.4. Denmark Pharmaceutical Third-party Logistics Market, 2021 - 2034 (USD Million)

9.4.8. Sweden

9.4.8.1. Key Country Dynamics

9.4.8.2. Competitive Scenario

9.4.8.3. Regulatory Framework

9.4.8.4. Sweden Pharmaceutical Third-party Logistics Market, 2021 - 2034 (USD Million)

9.4.9. Norway

9.4.9.1. Key Country Dynamics

9.4.9.2. Competitive Scenario

9.4.9.3. Regulatory Framework

9.4.9.4. Norway Pharmaceutical Third-party Logistics Market, 2021 - 2034 (USD Million)

9.5. Asia Pacific

9.5.1. Asia Pacific Pharmaceutical Third-party Logistics Market, 2021 - 2034 (USD Million)

9.5.2. Japan

9.5.2.1. Key Country Dynamics

9.5.2.2. Competitive Scenario

9.5.2.3. Regulatory Framework

9.5.2.4. Japan Pharmaceutical Third-party Logistics Market, 2021 - 2034 (USD Million)

9.5.3. China

9.5.3.1. Key Country Dynamics

9.5.3.2. Competitive Scenario

9.5.3.3. Regulatory Framework

9.5.3.4. China Pharmaceutical Third-party Logistics Market, 2021 - 2034 (USD Million)

9.5.4. India

9.5.4.1. Key Country Dynamics

9.5.4.2. Competitive Scenario

9.5.4.3. Regulatory Framework

9.5.4.4. India Pharmaceutical Third-party Logistics Market, 2021 - 2034 (USD Million)

9.5.5. South Korea

9.5.5.1. Key Country Dynamics

9.5.5.2. Competitive Scenario

9.5.5.3. Regulatory Framework

9.5.5.4. South Korea Pharmaceutical Third-party Logistics Market, 2021 - 2034 (USD Million)

9.5.6. Australia

9.5.6.1. Key Country Dynamics

9.5.6.2. Competitive Scenario

9.5.6.3. Regulatory Framework

9.5.6.4. Australia Pharmaceutical Third-party Logistics Market, 2021 - 2034 (USD Million)

9.5.7. Thailand

9.5.7.1. Key Country Dynamics

9.5.7.2. Competitive Scenario

9.5.7.3. Regulatory Framework

9.5.7.4. Thailand Pharmaceutical Third-party Logistics Market, 2021 - 2034 (USD Million)

9.6. Latin America

9.6.1. Latin America Pharmaceutical Third-party Logistics Market, 2021 - 2034 (USD Million)

9.6.2. Brazil

9.6.2.1. Key Country Dynamics

9.6.2.2. Competitive Scenario

9.6.2.3. Regulatory Framework

9.6.2.4. Brazil Pharmaceutical Third-party Logistics Market, 2021 - 2034 (USD Million)

9.6.3. Argentina

9.6.3.1. Key Country Dynamics

9.6.3.2. Competitive Scenario

9.6.3.3. Regulatory Framework

9.6.3.4. Argentina Pharmaceutical Third-party Logistics Market, 2021 - 2034 (USD Million)

9.7. MEA

9.7.1. MEA Pharmaceutical Third-party Logistics Market, 2021 - 2034 (USD Million)

9.7.2. South Africa

9.7.2.1. Key Country Dynamics

9.7.2.2. Competitive Scenario

9.7.2.3. Regulatory Framework

9.7.2.4. South Africa Pharmaceutical Third-party Logistics Market, 2021 - 2034 (USD Million)

9.7.3. Saudi Arabia

9.7.3.1. Key Country Dynamics

9.7.3.2. Competitive Scenario

9.7.3.3. Regulatory Framework

9.7.3.4. Saudi Arabia Pharmaceutical Third-party Logistics Market, 2021 - 2034 (USD Million)

9.7.4. UAE

9.7.4.1. Key Country Dynamics

9.7.4.2. Competitive Scenario

9.7.4.3. Regulatory Framework

9.7.4.4. UAE Pharmaceutical Third-party Logistics Market, 2021 - 2034 (USD Million)

9.7.5. Kuwait

9.7.5.1. Key Country Dynamics

9.7.5.2. Competitive Scenario

9.7.5.3. Regulatory Framework

9.7.5.4. Kuwait Pharmaceutical Third-party Logistics Market, 2021 - 2034 (USD Million)

Chapter 10. Competitive Landscape

10.1. Company Categorization

10.2. Company Market Position Analysis, 2024

10.3. Company Profiles

10.3.1. CEVA Logistics

10.3.1.1. Company overview

10.3.1.2. Financial performance

10.3.1.3. Service benchmarking

10.3.1.4. Strategic initiatives

10.3.2. Cencora Corporation (ICS)

10.3.2.1. Company overview

10.3.2.2. Financial performance

10.3.2.3. Service benchmarking

10.3.2.4. Strategic initiatives

10.3.3. DB SCHENKER

10.3.3.1. Company overview

10.3.3.2. Financial performance

10.3.3.3. Service benchmarking

10.3.3.4. Strategic initiatives

10.3.4. Kuehne+Nagel

10.3.4.1. Company overview

10.3.4.2. Financial performance

10.3.4.3. Service benchmarking

10.3.4.4. Strategic initiatives

10.3.5. Kerry Logistics Network Limited

10.3.5.1. Company overview

10.3.5.2. Financial performance

10.3.5.3. Service benchmarking

10.3.5.4. Strategic initiatives

10.3.6. Cardinal Health

10.3.6.1. Company overview

10.3.6.2. Financial performance

10.3.6.3. Service benchmarking

10.3.6.4. Strategic initiatives

10.3.7. McKesson Corporation

10.3.7.1. Company overview

10.3.7.2. Financial performance

10.3.7.3. Service benchmarking

10.3.7.4. Strategic initiatives

10.3.8. EVERSANA.

10.3.8.1. Company overview

10.3.8.2. Financial performance

10.3.8.3. Service benchmarking

10.3.8.4. Strategic initiatives

10.3.9. Thermo Fisher Scientific Inc.

10.3.9.1. Company overview

10.3.9.2. Financial performance

10.3.9.3. Service benchmarking

10.3.9.4. Strategic initiatives

10.3.10. Knipper Health

10.3.10.1. Company overview

10.3.10.2. Financial performance

10.3.10.3. Service benchmarking

10.3.10.4. Strategic initiatives

Proceed To Buy

USD 4500
USD 3900
USD 1900
USD 1200

Customization Offered

  • check-img Cross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers